as 05-13-2024 4:00pm EST
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | HANOVER |
Market Cap: | 6.0M | IPO Year: | N/A |
Target Price: | $6.00 | AVG Volume (30 days): | 1.5M |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.39 | EPS Growth: | N/A |
52 Week Low/High: | $1.40 - $18.00 | Next Earning Date: | 05-10-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Young David | PCSA | Pres. Research & Development | Feb 6 '24 | Buy | $2.53 | 20,000 | $50,504.00 | 58,387 | SEC Form 4 |
Lin Patrick | PCSA | Chief Business - Strategy Off | Jan 31 '24 | Buy | $2.37 | 2,500 | $5,925.00 | 25,978 | SEC Form 4 |
Lin Patrick | PCSA | Chief Business - Strategy Off | Jan 31 '24 | Buy | $2.40 | 1,500 | $3,600.00 | 27,478 | SEC Form 4 |
Ng George K | PCSA | Chief Executive Officer | Jan 30 '24 | Buy | $2.70 | 10,000 | $27,000.00 | 20,000 | SEC Form 4 |
PCSA Breaking Stock News: Dive into PCSA Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
GlobeNewswire
14 days ago
GlobeNewswire
a month ago
Simply Wall St.
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago